{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T04:02:30Z","timestamp":1793851350827,"version":"4.6.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"16","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1038\/s41433-025-04027-2","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T14:10:04Z","timestamp":1758809404000},"page":"2852-2859","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The adverse effects of oral niacin\/nicotinamide - an overview of reviews"],"prefix":"10.1038","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2992-5990","authenticated-orcid":false,"given":"Su Ling","family":"Young","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1982-5005","authenticated-orcid":false,"given":"Gus","family":"Gazzard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"key":"4027_CR1","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1007\/s001250051536","volume":"43","author":"M Knip","year":"2000","unstructured":"Knip M, Douek IF, Moore WP, Gillmor HA, McLean AE, Bingley PJ, et al. Safety of high-dose nicotinamide: a review. Diabetologia. 2000;43:1337\u201345.","journal-title":"Diabetologia"},{"key":"4027_CR2","first-page":"7","volume":"25","author":"R Huber","year":"2020","unstructured":"Huber R, Wong A. Nicotinamide: an update and review of safety & differences from niacin. Skin Therapy Lett. 2020;25:7\u201311.","journal-title":"Skin Therapy Lett"},{"key":"4027_CR3","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1007\/BF02256096","volume":"11","author":"CC Shen","year":"2004","unstructured":"Shen CC, Huang HM, Ou HC, Chen HL, Chen WC, Jeng KC. Protective effect of nicotinamide on neuronal cells under oxygen and glucose deprivation and hypoxia\/reoxygenation. J Biomed Sci. 2004;11:472\u201381.","journal-title":"J Biomed Sci"},{"key":"4027_CR4","unstructured":"NLM. Clinical Trials.gov Search: Nicotinamide. Available at: https:\/\/www.clinicaltrials.gov\/search?intr=Nicotinamide."},{"key":"4027_CR5","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1126\/science.aal0092","volume":"355","author":"PA Williams","year":"2017","unstructured":"Williams PA, Harder JM, Foxworth NE, Cochran KE, Philip VM, Porciatti V, et al. Vitamin B(3) modulates mitochondrial vulnerability and prevents glaucoma in aged mice. Science. 2017;355:756\u201360.","journal-title":"Science"},{"key":"4027_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1001\/jamaophthalmol.2021.4576","volume":"140","author":"CG De Moraes","year":"2022","unstructured":"De Moraes CG, John SWM, Williams PA, Blumberg DM, Cioffi GA, Liebmann JM. Nicotinamide and pyruvate for neuroenhancement in open-angle glaucoma: a phase 2 randomized clinical trial. JAMA Ophthalmol. 2022;140:11\u20138.","journal-title":"JAMA Ophthalmol"},{"key":"4027_CR7","unstructured":"Institute SER. Targeting Metabolic Insufficiency (TAMING) Glaucoma Study A 2-year Multi-centre, Double-masked, Randomised, Placebo-controlled Trial of Nicotinamide (Vitamin B3) Supplementation in Glaucoma. Health Services Authority Singapore 2024. Available at: https:\/\/www.clinicaltrials.gov\/study\/NCT06731582?term=AREA%5BInterventionSearch%5D(NICOTINAMIDE)%20AND%20AREA%5BStudyType%5D(INTERVENTIONAL)&rank=4."},{"key":"4027_CR8","unstructured":"team TVs. The Vitamin B3 in Glaucoma Study (VBIGS): A 2-year Multi-centre, Double-masked, Randomised, Placebo-controlled Trial of Nicotinamide (Vitamin B3) Supplementation in Glaucoma. Australia New Zealand Clinical Trials Registry. 27th October 2023. Available at: https:\/\/www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?ACTRN=ACTRN12622000414718. Accessed 3rd June 24, 2024."},{"key":"4027_CR9","unstructured":"team Tt. The Glaucoma Nicotinamide Trial (TGNT). Available at: https:\/\/www.clinicaltrials.gov\/study\/NCT05405868?cond=Glaucoma&intr=Nicotinamide&rank=7. Accessed 3rd June, 2024."},{"key":"4027_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-021-05968-1","volume":"23","author":"CKS Leung","year":"2022","unstructured":"Leung CKS, Ren ST, Chan PPM, Wan KHN, Kam AKW, Lai GWK, et al. Nicotinamide riboside as a neuroprotective therapy for glaucoma: study protocol for a randomized, double-blind, placebo-control trial. Trials. 2022;23:45.","journal-title":"Trials"},{"key":"4027_CR11","unstructured":"Team CT. Nicotinamide and Pyruvate for Open Angle Glaucoma: A Randomized Clinical Study. Available at: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05695027#contacts."},{"key":"4027_CR12","unstructured":"G; G-HDL. Nicotinamide in Glaucoma (NAMinG): a randomised, placebo-controlled, multicentre, Phase III trial. National Institute for Health and Care Research (NIHR). Available at: https:\/\/fundingawards.nihr.ac.uk\/award\/NIHR132758. Accessed December 2024."},{"key":"4027_CR13","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.jclinepi.2015.06.005","volume":"69","author":"P Whiting","year":"2016","unstructured":"Whiting P, Savovi\u0107 J, Higgins JP, Caldwell DM, Reeves BC, Shea B, et al. ROBIS: A new tool to assess risk of bias in systematic reviews was developed. J Clin Epidemiol. 2016;69:225\u201334.","journal-title":"J Clin Epidemiol"},{"key":"4027_CR14","doi-asserted-by":"crossref","unstructured":"Fania L, Mazzanti C, Campione E, Candi E, Abeni D, Dellambra E. Role of Nicotinamide in Genomic Stability and Skin Cancer Chemoprevention. Int J Mol Sci. 2019;20:5946.","DOI":"10.3390\/ijms20235946"},{"key":"4027_CR15","doi-asserted-by":"publisher","first-page":"e14892","DOI":"10.1111\/dth.14892","volume":"34","author":"S Giacalone","year":"2021","unstructured":"Giacalone S, Spigariolo CB, Bortoluzzi P, Nazzaro G. Oral nicotinamide: The role in skin cancer chemoprevention. Dermatol Ther. 2021;34:e14892.","journal-title":"Dermatol Ther"},{"key":"4027_CR16","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1177\/12034754221078201","volume":"26","author":"L Mainville","year":"2022","unstructured":"Mainville L, Smilga AS, Fortin PR. Effect of Nicotinamide in Skin Cancer and Actinic Keratoses Chemoprophylaxis, and Adverse Effects Related to Nicotinamide: A Systematic Review and Meta-Analysis. J Cutan Med Surg. 2022;26:297\u2013308.","journal-title":"J Cutan Med Surg"},{"key":"4027_CR17","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3390\/biomedicines12081655","volume":"12","author":"S Babighian","year":"2024","unstructured":"Babighian S, Gattazzo I, Zanella MS, Galan A, D'Esposito F, Musa M, et al. Nicotinamide: Bright Potential in Glaucoma Management. Biomedicines. 2024;12:8.","journal-title":"Biomedicines"},{"key":"4027_CR18","doi-asserted-by":"crossref","unstructured":"Hwang ES, Song SB. Possible adverse effects of high-dose nicotinamide: mechanisms and safety assessment. Biomolecules 2020;10:687.","DOI":"10.3390\/biom10050687"},{"key":"4027_CR19","doi-asserted-by":"crossref","unstructured":"Shukla AG, Cioffi GA, Liebmann JM. Drug-induced liver injury during a glaucoma neuroprotection clinical trial. Journal of Glaucoma 2024;33:e58\u20139.","DOI":"10.1097\/IJG.0000000000002394"},{"key":"4027_CR20","unstructured":"Scientific Committee on Food. Opinion of the Scientific Committee on Food on the Tolerable Upper Intake Levels of Nicotinic Acid and Nicotinamide (Niacin). 2002. Available at: https:\/\/ec.eu-ropa.eu\/food\/sites\/food\/files\/safety\/docs\/sci-com_scf_out80j_en.pdf; Accessed 11 Dec 2024."},{"key":"4027_CR21","first-page":"58","volume":"31","author":"H Shahbazian","year":"2011","unstructured":"Shahbazian H, Zafar Mohtashami A, Ghorbani A, Abbaspour MR, Belladi Musavi SS, Hayati F, et al. Oral nicotinamide reduces serum phosphorus, increases HDL, and induces thrombocytopenia in hemodialysis patients: a double-blind randomized clinical trial. Nefrologia. 2011;31:58\u201365.","journal-title":"Nefrologia"},{"key":"4027_CR22","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1093\/ndt\/gfw042","volume":"32","author":"A Lenglet","year":"2017","unstructured":"Lenglet A, Liabeuf S, El Esper N, Brisset S, Mansour J, Lemaire-Hurtel AS, et al. Efficacy and safety of nicotinamide in haemodialysis patients: the NICOREN study. Nephrol Dial Transplant. 2017;32:870\u20139.","journal-title":"Nephrol Dial Transplant"},{"key":"4027_CR23","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1111\/j.1523-1755.2004.00482.x","volume":"65","author":"Y Takahashi","year":"2004","unstructured":"Takahashi Y, Tanaka A, Nakamura T, Fukuwatari T, Shibata K, Shimada N, et al. Nicotinamide suppresses hyperphosphatemia in hemodialysis patients. Kidney Int. 2004;65:1099\u20131104.","journal-title":"Kidney Int"},{"key":"4027_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.krcp.2013.02.001","volume":"32","author":"CW Park","year":"2013","unstructured":"Park CW. Niacin in patients with chronic kidney disease: Is it effective and safe? Kidney Res Clin Pract. 2013;32:1\u20132.","journal-title":"Kidney Res Clin Pract"},{"key":"4027_CR25","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","volume":"365","author":"WE Boden","year":"2011","unstructured":"Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255\u201367.","journal-title":"N Engl J Med"},{"key":"4027_CR26","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.atherosclerosis.2013.09.034","volume":"231","author":"G Brunner","year":"2013","unstructured":"Brunner G, Yang EY, Kumar A, Sun W, Virani SS, Negi SI, et al. The effect of lipid modification on peripheral artery disease after endovascular intervention trial (ELIMIT). Atherosclerosis. 2013;231:371\u20137.","journal-title":"Atherosclerosis"},{"key":"4027_CR27","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41591-023-02793-8","volume":"30","author":"M Ferrell","year":"2024","unstructured":"Ferrell M, Wang Z, Anderson JT, Li XS, Witkowski M, DiDonato JA, et al. A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk. Nature Medicine. 2024;30:424\u201334.","journal-title":"Nature Medicine"},{"key":"4027_CR28","doi-asserted-by":"publisher","first-page":"e192224","DOI":"10.1001\/jamanetworkopen.2019.2224","volume":"2","author":"E D'Andrea","year":"2019","unstructured":"D\u2019Andrea E, Hey SP, Ramirez CL, Kesselheim AS. Assessment of the role of niacin in managing cardiovascular disease outcomes: a systematic review and meta-analysis. JAMA Netw Open. 2019;2:e192224.","journal-title":"JAMA Netw Open"},{"key":"4027_CR29","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1177\/1074248410361337","volume":"15","author":"JK Duggal","year":"2010","unstructured":"Duggal JK, Singh M, Attri N, Singh PP, Ahmed N, Pahwa S, et al. Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease. J Cardiovasc Pharmacol Ther. 2010;15:158\u201366.","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"4027_CR30","first-page":"Cd009744","volume":"6","author":"S Schandelmaier","year":"2017","unstructured":"Schandelmaier S, Briel M, Saccilotto R, Olu KK, Arpagaus A, Hemkens LG, et al. Niacin for primary and secondary prevention of cardiovascular events. Cochrane Database Syst Rev. 2017;6:Cd009744.","journal-title":"Cochrane Database Syst Rev"},{"key":"4027_CR31","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1146\/annurev.nutr.28.061807.155443","volume":"28","author":"KL Bogan","year":"2008","unstructured":"Bogan KL, Brenner C. Nicotinic acid, nicotinamide, and nicotinamide riboside: a molecular evaluation of NAD+ precursor vitamins in human nutrition. Annu Rev Nutr. 2008;28:115\u201330.","journal-title":"Annu Rev Nutr"},{"key":"4027_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12948","volume":"7","author":"SA Trammell","year":"2016","unstructured":"Trammell SA, Schmidt MS, Weidemann BJ, Redpath P, Jaksch F, Dellinger RW, et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat Commun. 2016;7:12948.","journal-title":"Nat Commun"},{"key":"4027_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03421-7","volume":"9","author":"CR Martens","year":"2018","unstructured":"Martens CR, Denman BA, Mazzo MR, Armstrong ML, Reisdorph N, McQueen MB, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD(+) in healthy middle-aged and older adults. Nat Commun. 2018;9:1286.","journal-title":"Nat Commun"},{"key":"4027_CR34","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1177\/0960327115626254","volume":"35","author":"D Conze","year":"2016","unstructured":"Conze D, Crespo-Barreto J, Kruger C. Safety assessment of nicotinamide riboside, a form of vitamin B3. Human & Experimental Toxicology. 2016;35:1149\u201360.","journal-title":"Human & Experimental Toxicology"},{"key":"4027_CR35","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1684\/ejd.2017.3025","volume":"27","author":"F Drago","year":"2017","unstructured":"Drago F, Ciccarese G, Cogorno L, Calvi C, Marsano LA, Parodi A. Prevention of non-melanoma skin cancers with nicotinamide in transplant recipients: a case-control study. Eur J Dermatol. 2017;27:382\u20135.","journal-title":"Eur J Dermatol"},{"key":"4027_CR36","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.2215\/CJN.04211007","volume":"3","author":"SC Cheng","year":"2008","unstructured":"Cheng SC, Young DO, Huang Y, Delmez JA, Coyne DW. A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients. Clin J Am Soc Nephrol. 2008;3:1131\u201338.","journal-title":"Clin J Am Soc Nephrol"},{"key":"4027_CR37","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1093\/nutrit\/nux011","volume":"75","author":"C Minto","year":"2017","unstructured":"Minto C, Vecchio MG, Lamprecht M, Gregori D. Definition of a tolerable upper intake level of niacin: a systematic review and meta-analysis of the dose-dependent effects of nicotinamide and nicotinic acid supplementation. Nutr Rev. 2017;75:471\u201390.","journal-title":"Nutr Rev"},{"key":"4027_CR38","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.2337\/diacare.19.12.1357","volume":"19","author":"P Pozzilli","year":"1996","unstructured":"Pozzilli P, Browne PD, Kolb H. Meta-analysis of nicotinamide treatment in patients with recent-onset IDDM. The Nicotinamide Trialists. Diabetes Care. 1996;19:1357\u201363.","journal-title":"Diabetes Care"},{"key":"4027_CR39","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3177\/jnsv.68.151","volume":"68","author":"J Pietris","year":"2022","unstructured":"Pietris J. The Role of NAD(+) and Nicotinamide (Vitamin B3) in Glaucoma: A Literature Review. J Nutr Sci Vitaminol (Tokyo). 2022;68:151\u20134.","journal-title":"J Nutr Sci Vitaminol (Tokyo)"},{"key":"4027_CR40","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/exd.13819","volume":"28","author":"VA Snaidr","year":"2019","unstructured":"Snaidr VA, Damian DL, Halliday GM. Nicotinamide for photoprotection and skin cancer chemoprevention: A review of efficacy and safety. Exp Dermatol. 2019;28:15\u201322.","journal-title":"Exp Dermatol"},{"key":"4027_CR41","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/j.jaad.2020.04.123","volume":"84","author":"KG Thompson","year":"2021","unstructured":"Thompson KG, Kim N. Dietary supplements in dermatology: A review of the evidence for zinc, biotin, vitamin D, nicotinamide, and Polypodium. J Am Acad Dermatol. 2021;84:1042\u201350.","journal-title":"J Am Acad Dermatol"},{"key":"4027_CR42","doi-asserted-by":"publisher","first-page":"e12731","DOI":"10.1097\/MD.0000000000012731","volume":"97","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Ma T, Zhang P. Efficacy and safety of nicotinamide on phosphorus metabolism in hemodialysis patients: A systematic review and meta-analysis. Medicine (Baltimore). 2018;97:e12731.","journal-title":"Medicine (Baltimore)"},{"key":"4027_CR43","doi-asserted-by":"crossref","unstructured":"Final report of the safety assessment of niacinamide and niacin. Int J Toxicol 2005;24:1\u201331.","DOI":"10.1080\/10915810500434183"},{"key":"4027_CR44","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S0140-6736(04)15786-3","volume":"363","author":"EA Gale","year":"2004","unstructured":"Gale EA, Bingley PJ, Emmett CL, Collier T. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet. 2004;363:925\u201331.","journal-title":"Lancet"},{"key":"4027_CR45","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1177\/089686080902900515","volume":"29","author":"DO Young","year":"2009","unstructured":"Young DO, Cheng SC, Delmez JA, Coyne DW. The effect of oral niacinamide on plasma phosphorus levels in peritoneal dialysis patients. Perit Dial Int. 2009;29:562\u20137.","journal-title":"Perit Dial Int"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04027-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04027-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04027-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T12:07:06Z","timestamp":1762171626000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04027-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":45,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["4027"],"URL":"https:\/\/doi.org\/10.1038\/s41433-025-04027-2","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,25]]},"assertion":[{"value":"21 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Young has no conflicts of interest to declare. Gazzard reported personal fees from Alcon Laboratories, Allergan\/AbbVie, Lumenis, Lumibird\/Quantel\/Ellex, Zeiss and personal fees from Ciliatech, Elios Vision, Genentech\/Roche, Glaukos, Haag-Streit Group, Iantrek, iStar Medical, Oertli, Reichert, Ripple Therapeutics, Santen, Sight Sciences, Thea, and Vialase and serving as a member of organising or meeting programme committees for American Society of Cataract and Refractive Surgery, British Council for Prevention of Blindness, European Glaucoma Society, European Society Of Cataract & Refractive Surgeons, European Vision Institute Clinical Research Network, Glaucoma-UK, Moorfields NHS Trust, National Institute for Health and Care Excellence, Royal College of Ophthalmologists UK and \u00c9ire Glaucoma Society, University College London, and World Glaucoma Congress outside the submitted work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}